Vyome Holdings (HIND) Price to Book (2025 - 2026)
Vyome Holdings (HIND) posted Price to Book of 2.06 for Q2 2026, up 9.98% on a QoQ basis from 1.88 in Q1 2026.
Powered by 
Analysis
Vyome Holdings (HIND) Price to Book (2025 - 2026) Analysis & Trends
Vyome Holdings has reported Price to Book for 2 years, with the latest figure at 2.06 in Q2 2026.
- On a quarterly basis, Price to Book changed N/A year-over-year to 2.06 in Q2 2026; TTM through Jun 2026 was 2.06, a N/A change from a year earlier, with the FY2025 full-year figure at 1.98, changed N/A from the prior year.
- Price to Book was 2.06 for Q2 2026 at Vyome Holdings, up from 1.88 in the prior quarter.
- The five-year high for Price to Book was 3.65 in Q3 2025, with the low at 1.88 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Vyome Holdings | 15.58 Mn | 8.96 Mn | 11,658.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.06 |
| Mar 31, 2026 | 1.88 |
| Dec 31, 2025 | 1.98 |
| Sep 30, 2025 | 3.65 |